High-throughput NaV1.9 assay to advance pain therapies
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
List view / Grid view
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
4 April 2025 | By Eurofins Discovery
Join Dr. Francisca Neethling from Eurofins Discovery to explore the comprehensive process of ADC development, covering payload linker design, optimization, and the bioanalytical and functional characterization of ADC molecules.
19 March 2025 | By Eurofins DiscoverX
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
9 January 2025 | By Eurofins DiscoverX
Gain valuable insights into the latest advancements in obesity drug discovery and enhance your research capabilities.
17 July 2024 | By Eurofins Discovery
Join this webinar to hear from Eurofins Discovery on the latest offerings for drug-drug interaction assessments using CRISPR KO/KI MDCKII cell lines
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
20 June 2024 | By Eurofins DiscoverX
Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules.
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
9 April 2024 | By Eurofins Discovery
Join Dr Carleton Sage to learn about predicting ADME properties as a key approach to improving the efficiency of small molecule drug discovery. AI ADME model development approaches and case studies within drug discovery projects will be discussed.
22 February 2024 | By Dr. Reece Gardner
Hear how Dr. Reece Gardner from Curve Therapeutics uses the Dianthus instrument with Spectral Shift technology to validate Microcycle® hits.
The guide provides examples of how Transcreener allowed rapid assay development to enable screening for kinases in innate immune pathways.
In this guide, we provide an overview of the DDR and innate immune pathway and describe Transcreener Assays and Assay Systems for key targets.
Tips and tricks for fully leveraging Advanced Flow Cytometry.
Utilizing Advanced High-Throughput Flow Cytometry to Quantify Direct and Competitive Live Cell Antibody Binding